Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ABC’s Of Hepatitis C Treatment Readiness and Follow-up Geri Hirsch RN-NP Nurse Practitioner Hepatology [email protected] Overview of Presentation • HCV screening/testing • Pretreatment counseling • Encouraging adherence • Managing adverse events Screening (1) Anyone with RISK BEHAVIOURS/POTENTIAL EXPOSURES to HCV • High Risk – Injection drug use (IDU) – Incarceration – Born, traveled, or resided in a region in which HCV infection is more common – Receipt of health care where there is a lack of universal precautions (nosocomial transmission) – Blood transfusion, blood products, or organ transplant before 1992 in Canada http://www.phac-aspc.gc.ca/hepc/pubs/pdf/hepc_guide-eng.pdf (1) Anyone with RISK BEHAVIOURS/POTENTIAL EXPOSURES to HCV • Intermediate Risk – Hemodialysis – Infant born to mother with HCV infection – Needle stick injuries • Other Risks Associated With HCV EXPOSURE – Sharing sharp instruments/personal hygiene materials – with HCV+ person (e.g., razors, scissors, nail clippers, toothbrush) – Tattooing, body piercing, scarification, female genital mutilation or other ceremonial rituals – Intranasal (snorting) & inhalation drug use – Homelessness, residency in group homes or shelters – Higher-risk sexual behaviour http://www.phac-aspc.gc.ca/hepc/pubs/pdf/hepc_guide-eng.pdf (2) Anyone with CLINICAL CLUES suspicious for hepatitis C infection (and above risk factors) • Abnormal liver biochemistry (e.g., ALT) • Drug and/or alcohol dependency (past or present) • Blood diseases requiring multiple transfusions of blood products (e.g., hemophilia, thalassemia, sickle cell • anemia) • • HIV infection • Signs of chronic liver disease (e.g., hepatomegaly +/• splenomegaly, spider nevi, palmar erythema, jaundice) • Vasculitis (due to associated cryoglobulinemia) • History of unexplained renal impairment HBV infection • Non-Hodgkin’s lymphoma http://www.phac-aspc.gc.ca/hepc/pubs/pdf/hepc_guide-eng.pdf Hepatitis C Treatment HCV Standard of Care Therapy: Dosing Recommendations Medication HCV Genotypes 1 or 4 HCV Genotypes 2 or 3 180 μg/wk SQ (hemodialysis: reduce to 135 μg/wk SQ) PegIFN alfa-2a[1] • Ribavirin[2] 200 mg tablets in 2 divided doses/day • 1000 mg/day (< 75 kg) • 1200 mg/day (≥ 75 kg) • 800 mg/day 1.5 μg/kg/wk SQ (If CrCl 30-50 mL/min: reduce dose by 25%; if CrCl 10-29 mL/min: reduce dose by 50%) PegIFN alfa-2b[3] • Ribavirin[4] 200 mg capsules in 2 divided doses/day • • • • ≤ 65 kg: 800 mg/day 66-80 kg: 1000 mg/day > 80-105 kg: 1200 mg/day > 105 kg: 1400 mg/day • • • • ≤ 65 kg: 800 mg/day 66-80 kg: 1000 mg/day > 80-105 kg: 1200 mg/day > 105 kg: 1400 mg/day 1. Peginterferon alfa-2a [package insert]. 2010. 2. Ribavirin tablets [package insert]. 2010. 3. Peginterferon alfa-2b [package insert]. 2010. 4. Ribavirin capsules [package insert]. 2010. HCV Genotype and Response 24 wks RBV800mg/day+pegIFN alfa 2a 90 80 24 wks of RBV 1000/1200 mg/day +pegIFN alfa 2a SVR (%) 70 48 wks RBV800mg/day+pegIFN alfa 2a 60 50 48 wks of RBV 1000/1200 mg/day +pegIFN alfa 2a 40 30 20 10 0 Geno 1 Geno 2+3 Advanced Fibrosis Geno1 Geno 2+3 Minimal Fibrosis Hadziyannis SJ, et al. Ann Intern Med. 2004;140:346-355. Current and Future Treatments Future treatment 80 70 SVR (%) 60 Current treatment 50 40 30 20 10 0 Naïve non responders Naïve non responders 1. Poordad F, et al. AASLD 2010. Abstract LB-4. 2. Jacobson IM, et al. AASLD 2010. Abstract 211. 3. Bacon BR, et al. AASLD 2010. Abstract 216. 4. These data are available in press release format only, have not been peer reviewed, may be incomplete, and we await presentation or publication in a peer-reviewed format before conclusions should be made from these data. Predictors of Treatment Response Patient Factors Virus Factors • Age • Genotype • Sex • HCV RNA level • Race • Weight • Insulin resistance • Fatty liver disease • Mental health • Drug/alcohol use • Cirrhosis • HIV coinfection • IL28B status Regimen Factors • Adherence to pegIFN/RBV • Weight-based RBV dosing (genotypes 1/4) • Reported improved response rates with protease inhibitors (in the future, for genotype 1 patients only) Response Definitions in Patients Receiving HCV Therapy Response definitions Time Point HCV RNA Level Rapid virologic response - RVR 4 wks into therapy Undetectable Early virologic response - EVR 12 wks into therapy Undetectable (complete) ≥ 2 log decrease from baseline (partial) End of treatment response - EOT End of therapy Sustained virologic response - SVR 6 mos post therapy Undetectable Ghany MG, et al. Hepatology. 2009;49:1335-1374. Undetectable Preparing the Patient for HCV Therapy • Provide and verify patient’s/family’s understanding of basic information about – – – – HCV transmission, prognosis, treatment, adverse event management • Obtain and discuss – patient’s /family’s willingness – adherence to medications – need for visits/lab follow-ups Preparing the Patient for HCV Therapy • Social assessment – housing, – disability, – social supports, – transportation, finances, drug plan • Educate – alcohol, herbals, – hepatotoxins, – safe injection techniques* • Ensure immunizations for HAV, HBV, pneumococcal, and seasonal influenza Preparing the Patient for HCV Therapy • Cautionary Uses – Cardiovascular disease – Autoimmune disease • Cryoglobulinemia related symptoms – Psychiatry history/suicide – Alcohols and substance misue – Other • DM,seziure disorder,decomplenstated liver disease ,renal diseasem lung disease, retinopathy, hemoglobinopathies Preparing the Patient for HCV Therapy • Provide and verify patient’s understanding of basic information of side effect management • Encourage patient’s/family’s active participation in treatment decisions and ability to ask questions • Review laboratory parameters and urine pregnancy test* – Serum ALT, AST, bilirubin, alkaline phosphatase, albumin, serum creatinine / BUN, TSH, glucose, urinalysis – prothrombin time/INR,CBC with differential and platelet count,HIV and hepatitis B surface antigen – ANA*,genotype, viral load**,occular exam* – weight Preparing the Patient for HCV Therapy • Additional Tests – Chest x ray, PA and LAT – Cardiac assessment - EKG and in consultations with MD consider a cardiology consult – Mental Health Assessment – Abdominal ultrasound – Iron saturations (and hemochromatosis gene test if indicated – Serum cooper, ceruloplasmin, and alpha 1 if indicated Preparing the Patient for HCV Therapy • Assure effective contraception and reinforce issue of contraception • Administer/demonstrate techniques for pegIFN injections • Provide information on safe disposal of needles PegIFN Administration • PegIFN alfa-2a[1] – Premixed vials/prefilled syringes – Dose is not weight adjusted: 180 μg SQ every wk – Syringes are overfilled; ensure correct dose before administration • PegIFN alfa-2b[2] – Vials/syringes need to be reconstituted before use – Redipen – Weight-adjusted dose: 1.5 μg/kg per dose every wk • Allow to come to room temperature before use 1. Peginterferon alfa-2a [package insert]. 2010. 2. Peginterferon alfa-2b [package insert]. 2010. Encouraging Adherence Adherence to PegIFN/RBV • Not all patients take al their medication. – In one US study 60% were adherent [1] • 80/80/80 phenomenon – taking > 80 % of medications correlates with SVR[2,3] • Remember patients may overestimate adherence [4] • For some individuals a multidisciplinary team may be beneficial for adherence 1. Mitra D, et al. Value Health. 2010;13:479-486. 2. McHutchison JG, et al. Gastroenterology. 2002;123:1061-1069. 3. Raptopoulou M, et al. J Viral Hepat. 2005;12:91-95. 4. Smith SR, et al. Ann Pharmacother. 2007;41:1116-1123. Major Predictors of Poor Adherence to Medication Patient and Treatment Factors •Treatment of asymptomatic disease •Presence of psychological comorbidities, especially depression •Patient’s lack of belief in treatment benefit •Treatment complexity •Adverse events of medication Osterberg L, et al. N Engl J Med. 2005;353:487-497. Other Factors • Poor relationship between the patient and provider • Inadequate follow-up or discharge preparation • Missed appointments • Cost of copayment, medication, or both Strategies for Improving Adherence to a Medication Regimen • Identify risk factors for poor adherence early – Look for strategies to mitigate some of the factors • Emphasize value of regimen and potential results to pts – Some patients are asymptomatic • Provide simple, clear instructions and simplified regimen • Encourage the use of medication-dispensing packaging – Blister packs may be helpful Osterberg L, et al. N Engl J Med. 2005;353:487-497. Strategies for Improving Adherence to a Medication Regimen • Customize regimen to pt lifestyle when possible – Injection days – weekend • Support from family members, friends, and community • Consider more “forgiving” medications – Medications with long half-lives, sustained release, or depot Managing Adverse Events PegIFN Adverse Events AE Occurring in > 20% of Pts, % PegIFN alfa-2a/RBV (n = 1035) PegIFN alfa-2b/RBV (n = 1019) 64/41 67/38 Headache 41 50 Nausea 34 40 Anemia 34 35 Rash 34 29 Neutropenia 31 26 25/20 25/25 Chills 23 39 Injection-site reactions 23 34 22/22 27/21 Dyspnea 22 21 Pyrexia 21 35 Anorexia 21 29 Alopecia 17 23 Fatigue/insomnia Irritability/depression Myalgia/arthralgia Peginterferon alfa-2b [package insert]. 2010. RBV Adverse Effects • Adverse events occurring more frequently when RBV added to pegIFN vs pegIFN alone – Hemolytic anemia – Headache – Cough/SOB – Gastrointestinal upset – Rash – Insomnia – Teratogenicity Peginterferon alfa-2b [package insert]. 2010. Peginterferon alfa-2a [package insert]. 2010. Adverse Event Management • Anticipate adverse events – Common and occur in nearly all patients – Severity and nature of toxicity is highly variable – If events are not managed well result …Negative impact on treatment outcome and quality of life – Adverse event management starts before treatment begins • Preemptive measures – Chronic health conditions are stable – Assess chronic health conditions to ensure they will not be significantly impacted with treatment side effects – Provide supportive care during therapy • During current treatment with pegIFN/RBV[1] – 10% to 14% of patients discontinue treatment due to adverse event • Monitor closely since fatalities can occur 1. Seeff LB, et al. Semin Liver Dis. 2010;30:348-360. Supportive Therapy for HCV Treatment-Related Adverse Events Adverse Event Potential Interventions Flulike symptoms (fever, chills, HA, myalgias, arthralgias, fatigue) • Acetaminophen (≤ 2 grams/day) * • Bed rest • Fluids (noncaffeinated) 8-10 glasses/day Fatigue • • • • Mood changes (depression, suicidal/ homicidal tendencies, anxiety, irritability) • Avoid stimulants like caffeine, Ck TSH • Antidepressants (eg, SSRI), psych referral* • Short-acting benzodiazepines may help Insomnia • Develop good sleep patterns * • Limit fluid intake/caffeine before bedtime • Consider sleep aids (eg, diphenhydramine, trazodone, zolpidem) Administer IFN at bedtime Low-impact exercise Short naps, adjust work schedule Assess for anemia, TSH.. Supportive Therapy for HCV TreatmentRelated Adverse Events Adverse Event Potential Interventions Nausea/vomiting/anorexia • • • • • Take RBV with food Eat 6-8 small meals per day Ginger may help: tea, ale, syrup Carbonated fluids, jello drinks Provide prophylactic antiemetics (eg, prochlorperazine) Diarrhea • • • • Drink noncaffeinated fluids Increase fiber in diet (cereal, toast, rice), BRAT diet Avoid foods that are spicy, greasy, acidic Consider antidiarrheals or psyllium Skin irritation (injection-site reactions, dry skin, rashes) • Rotate injection sites • Take cool baths and use moisturizing soaps • Consider topical steroid cream or oral antihistamines Hair loss/thinning Education, wigs; reversible/temporary as hair grows back RBV-Induced Anemia • RBV-induced anemia correlates with achieving RVR/SVR – Mean maximum Hb decrease of 2.9-3.1 g/dL in first 6-8 wks[1,2] – Occurs early within first 1-2 wks and remains low – Anemia during the first 4-8 wks associated with improved probability of achieving RVR and/or SVR[3] – Can worsen fatigue, SOB, CV, quality of life, and lead to discontinuation of treatment – Follow product monograph for dose modification 1. Ribavirin tablets [package insert]. 2010. 2. Ribavirin capsules [package insert]. 2010. 3. Sulkowski MS, et al. Gastroenterology. 2010;139:1602-1611. Managing Hematologic Adverse Events • Anemia – Specific thresholds for considering RBV dose reduction, discontinuation, and/or EPO * – Note FDA warnings regarding risks associated with ESAs • Neutropenia – Specific thresholds for considering pegIFN dose reduction, therapy discontinuation, and/or G-CSF* • Thrombocytopenia – Specific thresholds for considering pegIFN dose reduction, therapy discontinuation See package inserts for details Laboratory monitoring for efficacy and treatment toxicity • Patients on PEG-Interferon combination therapy should have: – hematology and blood chemistry testing before the start of treatment and then periodically thereafter. – In the clinical trials CBC (including hemoglobin, neutrophil and platelet counts) and chemistries (including AST, ALT, bilirubin, and uric acid) were measured during the treatment period at weeks 2, 4, 8, 12, and then at 6-week intervals or more frequently if abnormalities developed. – TSH levels were measured every 12 weeks during the treatment period. See package inserts for details Laboratory monitoring for efficacy and treatment toxicity • Genotype non 2,3 – HCV viral load baseline – HCV viral load week 12 – HCV RNA week 24 * – HCV RNA week 48 – HCV RNA week 72 • Genotype non 2,3 – HCV RNA baseline – HCV RNA week 12 – HCV RNA at the end of treatment* – HCV RNA 24 week after completing treatment Laboratory monitoring for efficacy and treatment toxicity • Patients on PEG-Interferon combination therapy should have: – – – – – – – – HCV RNA/VL at baseline HCV RNA VL at week 12 ( non genotype 2,3) HCV PCR at week 12 (genotype 2 and 3) HCV PCR at week 24 ( non genotype 2,3) HCV PCR at week 24 ( non genotype 2,3) HCV PCR at week 48( non genotype 2,3) HCV PCR at week 48( non genotype 2,3) HCV PCR at week 72 ( non genotype 2,3) See package inserts for details Canadian Consensus Guidelines-Management of Hepatitis C , 2007 Canadian Consensus Guidelines-Management of Hepatitis C , 2007 Nursing Role in Patient Education and HCV Drug Therapy Management Patient Education Drug Therapy Management Anticipated benefits and risks of treatment Baseline assessment for contraindications to therapy Lifestyle changes Injection training and/or administration of injections Anticipated treatment duration/FU and need for adherence Laboratory monitoring for efficacy and treatment toxicity Prevention of disease progression Assessment and evaluation of •Avoid hepatotoxins—Acetaminophen, adherence alcohol, herbals, NSAIDs •Vaccine advocates—hepatitis A and B, influenza, pneumococcal Reduce risk of HCV transmission Management of treatment toxicity Marino EL, et al. J Manag Care Pharm. 2009;15:147-150. Smith JP, et al. Am J Health Syst Pharm. 2007;64:632-636. Success is dependent on effort and teamwork .